The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]

As China continues to evolve its pharmaceutical regulatory landscape, organizations operating within or in partnership with the Chinese market must proactively adapt to remain compliant and competitive. The National Medical Products Administration (NMPA) has outlined […]

In a significant move to reshape its pharmaceutical landscape, China has unveiled a comprehensive guideline aimed at deepening the reform of drug and medical device regulation. Issued by the General Office of the State Council […]